Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Columbia University

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Lymphoid Malignancies; Hodgkin Lymphoma; Non-hodgkin Lymphoma; Lymphoma

Treatments: Drug: Oral 5-Azacitidine 200 MG; Drug: Romidepsin 14 MG/M2; Drug: Oral 5-Azacitidine 100 MG; Drug: RomiDEPsin 10 MG/M2; Drug: Oral 5-Azacitidine 300 MG

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01998035

AAAM3752

Details and patient eligibility

About

This is an open label, phase I/IIa, 3 x 3 dose escalation study with an initial phase I followed by a disease focused phase II.

The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combinations of oral 5-azacitidine and romidepsin in patients with lymphoma. The safety and toxicity of this combination will be evaluated throughout the entire study.

If the combination of oral 5-azacitidine and romidepsin is found to be feasible and an MTD is established, the phase II part of the study will be initiated.

Phase II will consist of a 2 stage design of the combination of oral 5-azacitidine and romidepsin for patients with relapsed or refractory T-cell lymphomas.

Full description

Subjects will receive oral 5-azacitidine and romidepsin, administered as follows: oral 5-azacitidine from Days 1-14 (Dose cohorts -1 to 5) or Days 1-21 (Dose cohort 6); and romidepsin administered intravenously on Days 8 (Dose cohorts 1-4) of a 28 day cycle, and Day 22 (Dose cohorts 5 and 6) of a 35 day cycle. Cohorts of 3 patients will be enrolled sequentially as outlined in the dose escalation scheme. Once the MTD is reached the Phase II part of the protocol will be initiated in patients with T-Cell Lymphoma.

Enrollment: 58 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Phase I: Histologically confirmed relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma (WHO criteria), with no accepted curative options.
• Phase II: Relapsed or refractory T-cell lymphoma, including patients with central nervous system (CNS) involvement or lymphomatous meningitis are allowed on study.
• Relapsed or refractory disease following frontline chemotherapy. No upper limit for the number of prior therapies. Patients may have relapsed after prior autologous or allogeneic stem cell transplant.
• Evaluable Disease in the Phase I, and measurable disease for the Phase II.
• Age > or = 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status < or = 2.
• Patients must have adequate organ and marrow function.
• Negative urine or serum pregnancy test for females of childbearing potential.
• All females of childbearing potential must use an effective barrier method of contraception during the treatment period and for at least 1 month thereafter. Male subjects should use a barrier method of contraception during the treatment period and for at least 3 months thereafter.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• Prior Therapy

  • Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
  • Systemic steroids that have not been stabilized ( ≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs.
  • No other concurrent investigational agents are allowed.

• History of allergic reactions to Oral 5-azacitidine or Romidepsin.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant women.

• Nursing women.

• Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 3 years.

• Patients known to be Human Immunodeficiency Virus (HIV)-positive.

• Patients with active hepatitis A, hepatitis B, or hepatitis C infection.

• Concomitant use of CYP3A4 inhibitors.

• Any known cardiac abnormalities.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

58 participants in 7 patient groups

R/O: Level -1

Experimental group

Description:

Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2, Day 8), cycle length (28 days)

Treatment:

Drug: RomiDEPsin 10 MG/M2

Drug: Oral 5-Azacitidine 100 MG

R/O: Level 1

Experimental group

Description:

Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2, Days 8 and 15), cycle length (28 days)

Treatment:

Drug: RomiDEPsin 10 MG/M2

Drug: Oral 5-Azacitidine 100 MG

R/O: Level 2

Experimental group

Description:

Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2, Days 8 and 15), cycle length (28 days)

Treatment:

Drug: RomiDEPsin 10 MG/M2

Drug: Oral 5-Azacitidine 200 MG

R/O: Level 3

Experimental group

Description:

Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2, Days 8 and 15), cycle length (28 days)

Treatment:

Drug: Oral 5-Azacitidine 300 MG

Drug: RomiDEPsin 10 MG/M2

R/O: Level 4

Experimental group

Description:

Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2, Days 8 and 15), cycle length (28 days)

Treatment:

Drug: Oral 5-Azacitidine 300 MG

Drug: Romidepsin 14 MG/M2

R/O: Level 5

Experimental group

Description:

Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2, Days 8, 15 and 22), cycle length (35 days)

Treatment:

Drug: Oral 5-Azacitidine 300 MG

Drug: Romidepsin 14 MG/M2

R/O: Level 6

Experimental group

Description:

Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2, Days 8, 15 and 22), cycle length (35 days)

Treatment:

Drug: Oral 5-Azacitidine 300 MG

Drug: Romidepsin 14 MG/M2